[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
申请人:Clark D. Jerry
公开号:US20050043309A1
公开(公告)日:2005-02-24
This invention relates to compounds of the formula 1
wherein G, D, A, Z, Q, X, Y, R
1
, and R
4
through R
7
are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.
[EN] HEPATITIS C INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE L'HÉPATITE C
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2011063502A1
公开(公告)日:2011-06-03
Compounds of Formula (I) wherein R1, R2, R3, R4 and R5 are defined herein, maintain good activity against NS3 proteases containing clinically relevant genotype 1 a R155K and genotype 1 b D168V resistance mutations. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
[EN] [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA<br/>[FR] [1,8]NAPHTYRIDIN-2-ONES ET COMPOSES APPARENTES DESTINES AU TRAITEMENT DE LA SCHIZOPHRENIE
申请人:WARNER LAMBERT CO
公开号:WO2005019215A1
公开(公告)日:2005-03-03
This invention relates to compounds of the Formula (1) wherein G, A, Z, Q, X, Y, and R1 and R2 are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system and other disorders.
[1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA
申请人:Clark D. Jerry
公开号:US20060287310A1
公开(公告)日:2006-12-21
This invention relates to compounds of the formula 1
wherein G, D, A, Z, Q, X, Y, R
1
, and R
4
through R
7
are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.